ABAstanda Beslanovna Bargandzhiya

Astanda Beslanovna Bargandzhiya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Astanda Beslanovna Bargandzhiya has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of direct oral anticoagulants in patients with implanted inferior vena cava filters: a systematic review and meta-analysis

    by I. V. Schastlivtsev, V. V. Kozlova, A. B. Bargandzhiya, K. V. Lobastov

    Nowadays, vitamin K antagonists (VKA) remain the anticoagulants of choice for patients with implanted inferior vena cava (IVC) filters, while the use of direct oral anticoagulants (DOACs) is controversial. Aim of the review – the study aimed to compare the efficacy and safety of DOACs and VKAs in patients with IVC filters. A systematic search for the relevant papers was performed in Medline (Pubmed) and the Cochrane Library according to the PRISMA guidelines. The inclusion criteria for the analysis were as follows: comparative studies of any design that enrolled patients with verified venous thromboembolism (VTE) who underwent IVC filter implantation and received long-term therapy with DOACs or VKAs with reported numbers of thrombotic and hemorrhagic complications within a follow-up of ≥3 months. The primary endpoints were VTE recurrence and major bleeding. Secondary endpoints included deep vein thrombosis (DVT), IVC thrombosis or filter occlusion, pulmonary embolism (PE), clinically relevant non-major (CRNM) bleeding, any bleeding, and all-cause mortality. Meta-analysis was performed using a random or fixed-effect model depending on the identified heterogeneity. As a result of the literature search was performed in July 2024 and identified 189 references, of which four articles were selected for full-text analysis after screening and excluding 174 irrelevant papers. The final qualitative analysis and quantitative synthesis included two retrospective cohort studies of 302 patients comparing rivaroxaban and warfarin. There were no significant differences between rivaroxaban and warfarin according to the prespecified endpoints. Rivaroxaban is the only DOAC studied in patients with IVC filters. Anticoagulation with rivaroxaban is not less effective and safe than with warfarin after IVC filter implantation.


  • Place and role of compression therapy in modern minimally invasive treatment of varicose veins

    by K.V. Lobastov, V.V. Kozlova, A.V. Kovalchuk, A.B. Bargandzhiya, L.A. Laberko

    Chronic venous disease (CVD), which includes varicose veins (VVs) of the lower limbs, is one of the most common and socially significant cardiovascular diseases. Despite the recognition of elastic compression as an essential method of CVD treatment, the benefits and feasibility of its usage during the perioperative period are being reconsidered. This narrative literature review aims to highlight the current evidence of the efficacy of elastic compression in relieving initial and residual vein-specific symptoms, reducing the risk of adverse events and VVs recurrence after surgical treatment. It also provides brief information about the mechanisms of action of compression therapy and discusses compliance issues. Nowadays, the concept of the influence of elastic compression on the diameter of veins and venous outflow velocity has been critically revised. It has been shown that deep veins are more sensitive to external compression, while it is impossible to reduce the caliber of superficial veins under the usual pressure. Extensive evidence indicates the efficacy of compression therapy in relieving venous symptoms, which may persist in 30—40% of patients after surgery. The usage of compression therapy perioperatively helps reduce the rate and severity of such adverse events as pain, bruising, and hyperpigmentation, as well as promotes the resorption of veins after sclerotherapy. However, the optimal mode and duration of compression have not been finally determined. Despite the presence of individual studies, the effect of compression therapy on the progression of CVD and the risk of VVs recurrence has not been proven. The main disadvantage of elastic compression is relatively low compliance, which varies between 26 and 74%. To improve it, both motivational conversations by the doctor and efforts by manufacturers to maintain maximal product quality while giving them optimal properties for comfortable wear are essential. Thus, compression therapy is still an important component of the perioperative treatment of VVs of the lower limb.


  • Efficacy and safety of increased doses of anticoagulants in COVID-19 patients: a systematic review and meta-analysis

    by Pirogov’s Russian National Research Medical University, Kirill Victorovich Lobastov, Evgeny Alekseevich Stepanov, Sergey Nikolaevich Tsaplin, Ilya Veniaminovich Schastlivtsev, Astanda Beslanovna Bargandzhiya, Leonid Alexandrovich Laberko, Grigory Vladimirovich Rodoman

    The aim of the study was to evaluate the efficacy and safety of increased doses of anticoagulants in comparison with standard doses in inpatients with COVID-19. Material and methods. A systematic review was carried out in October 2021 using the Pubmed database. The analysis included only randomized clinical trials with ≥200 participants that reported the death rate as the total number of cases or the percentage of patients. The primary outcome was all-cause mortality within the observation period. Additionally, the risk of arterial and venous thrombotic events, major and clinically relevant non-major bleeding was assessed. Results. Searching of Pubmed identified 8,903 references, of which the results of 6 randomized clinical trials (INSPIRATION, 3 platforms study in REMAP-CAP, ACTIV-4a, and ATTACC including stable and unstable patients, RAPID, ACTION and HEP-COVID) with the total of 5,228 patients were included in the final qualitative analysis and quantitative synthesis. Among all the patients, 2,660 received increased doses and 2,568 — standard doses of anticoagulants. The follow-up period varied from 21 to 30 days. The administration of increased doses did not affect the risk of death (OR, 0.95; 95 % CI, 0.73–1.24; I² = 59.14 %), but was associated with a reduced risk of thrombotic events (OR, 0.56; 95 % CI, 0.43–0.73; I² = 24.90 %), and an increased risk of major bleeding (OR, 1.86; 95 % CI, 1.23–2.80; I² = 0.00 %) or clinically relevant non-major bleeding (OR, 3.66; 95 % CI, 1.65–8.10; I² = 0.00 %). Within the sensitivity analysis, similar results were obtained in the subgroups of critically ill or stable patients and individuals with increased D-dimer. The maximal reduction in the risk of thrombotic events was found for the subgroup of patients with increased D-dimer (OR, 0.48; 95 % CI, 0.34–0.70; I² = 36.38 %). Conclusions. The use of increased doses of anticoagulants in inpatients with COVID-19 does not reduce the risk of death. Still, it is associated with a decrease in the risk of arterial and venous thrombosis and an increased risk of major bleeding.


  • Risk of post-thrombotic syndrome following direct oral anticoagulant intake: a systematic review and meta-analysis

    by K.V. Lobastov, I.V. Schastlivtsev, A.B. Bargandzhiya

    Посттромботическая болезнь (ПТБ) является отдаленным осложнением тромбоза глубоких вен. Существуют разрозненные сведения о преимуществах прямых оральных антикоагулянтов (ПОАК) по сравнению с антагонистами витамина K (АВК) в отношении названного исхода. ЦЕЛЬ ИССЛЕДОВАНИЯ Систематический обзор и метаанализ опубликованных данных. МАТЕРИАЛ И МЕТОДЫ Систематический обзор и метаанализ результатов релевантных исследований, идентифицированных в базе данных Pubmed, выполнены в марте 2021 г. В анализ включали работы, сообщающие о частоте регистрации ПТБ в соответствии с критериями Villalta при использовании ПОАК или альтернативного режима антикоагулянтной терапии. Изучали частоту и риск развития любой и тяжелой форм ПТБ. РЕЗУЛЬТАТЫ Идентифицировано 10 сравнительных исследований, включающих информацию о 3161 пациенте. Частота регистрации ПТБ на фоне применения ПОАК составила 30,8% (95% ДИ 22,2—39,3%), тяжелой формы ПТБ — 2,2% (95% ДИ 1,0—3,4%). Применение ПОАК по сравнению с АВК ассоциировалось с достоверным снижением риска развития любой формы ПТБ (ОШ 0,57, 95% ДИ 0,48—0,68; pp=0,010). Среди отдельных ПОАК индивидуальные данные были доступны только для ривароксабана по сравнению с АВК: ОШ 0,54 (95% ДИ 0,42—0,71; pp=0,019). Использование флавоноидов в дополнение к ривароксабану ассоциировалось с дополнительным снижением риска развития любой формы ПТБ (ОШ 0,14, 95% ДИ 0,06—0,31; p<0,001). ЗАКЛЮЧЕНИЕ Научные данные среднего качества предполагают, что у пациентов с тромбозом глубоких вен применение ПОАК вместо АВК ассоциируется со снижением риска развития любой и тяжелой форм ПТБ. Среди всех ПОАК только у ривароксабана есть индивидуальные данные, подтверждающие снижение риска ПТБ. Сочетание ривароксабана с флавоноидами может дополнительно улучшить результаты лечения.


  • Open Access

    COVID-19-associated coagulopathy: review of current recommendations for diagnosis, treatment and prevention

    by K. V. Lobastov, I. V. Schastlivtsev, O. Ya. Porembskaya, O. V. Dzenina, A. B. Bargandzhiya, S. N. Tsaplin, О. Я. Порембская

    The coronavirus infection COVID-19 is a highly contagious disease caused by the SARS-CoV-2 virus. Specific prothrombotic changes of the hemostasis system in COVID-19 are associated with increased incidence of venous thromboembolic complications. The article is a literature review on the diagnosis, treatment and prevention of coagulopathy and venous thromboembolic complications associated with COVID-19. 11 studies evaluating the frequency of registration of venous thromboembolic complications and 11 clinical recommendations on correction of coagulopathy published before May 22, 2020 have been studied. The frequency of venous thromboembolic complications was unexpectedly high: 8–13% in the general ward and 9–18% in the intensive care unit against the background of preventive measures. Preventive doses of anticoagulants, low-molecular weight heparins or unfractionated heparin are indicated to all hospitalized patients. Prolonged prophylaxis after discharge from hospital can be recommended for those at high risk of venous thromboembolic complications and low risk of bleeding. An increase in D-dimer may be considered as an indication for instrumental detection of venous thromboembolic complications. If there is a suspicion of venous thromboembolic complications, anticoagulant therapy at therapeutic doses can be started before the diagnosis is confirmed: during inpatient treatment preference should be given to low-molecular heparin or unfractionated heparin, after discharge from hospital it is recommended to transfer to direct oral anticoagulants for a period of at least 3 months. Routine prevention of venous thromboembolic complications in ambulatory patients is not recommended.


  • Intermittent Pneumatic Compression in Addition to Standard Prophylaxis of Postoperative Venous Thromboembolism in Extremely High-risk Patients (IPC SUPER): A Randomized Controlled Trial

    by Kirill Lobastov, Ekaterina Sautina, Eleanora Alencheva, Astanda Bargandzhiya, Ilya Schastlivtsev, Victor Barinov, Leonid Laberko, Grigoriy Rodoman, Valeriy Boyarintsev

    Objective: To assess the efficacy of adjunctive IPC to standard prophylaxis of postoperative VTE in patients at extremely high-risk. Summary of Background Data: The standard prophylaxis for postoperative VTE is insufficient in extremely high-risk patients. It is unclear whether an adjunctive use of IPC would result in a lower incidence of postoperative venous thrombosis. Methods: We randomly assigned patients who underwent major surgery and had a Caprini score of ≥11 to receive either IPC in addition to standard prophylaxis with anti-embolic stockings (pressure of 18–21 mm Hg at the ankle) and low-molecular-weight heparin (IPC group) or standard prophylaxis alone (control group). The primary outcome was an asymptomatic venous thrombosis of the lower limbs, as detected by duplex ultrasound scan performed before inclusion and every 3–5 days after surgery. Results: A total of 407 patients underwent randomization, of which 204 were assigned to the IPC group and 203 to the control group. The primary outcome occurred in 1 (0.5%) patient in the IPC group and 34 (16.7%) patients in the control group [relative risk, 0.03, 95% confidential interval (CI): 0.01–0.21]. Pulmonary embolism occurred in none of the 204 patients in the IPC group and in 5 (2.5%) patients in the control group (relative risk, 0.09; 95% CI, 0.01–1.63), and postoperative death occurred in 6 (2.9%) patients in the IPC group and 10 (4.9%) in the control group (relative risk, 0.50; 95% CI, 0.50–1.60). Conclusions: Among patients with a Caprini score of ≥11 who received standard prophylaxis for VTE, adjunctive IPC resulted in a significantly lower incidence of asymptomatic venous thrombosis.


  • Open Access

    COVID-19-associated coagulopathy: review of current recommendations for diagnosis, treatment and prevention

    by K. V. Lobastov, I. V. Schastlivtsev, O. Ya. Porembskaya, O. V. Dzenina, A. B. Bargandzhiya, S. N. Tsaplin, О. Я. Порембская

    The coronavirus infection COVID-19 is a highly contagious disease caused by the SARS-CoV-2 virus. Specific prothrombotic changes of the hemostasis system in COVID-19 are associated with increased incidence of venous thromboembolic complications. The article is a literature review on the diagnosis, treatment and prevention of coagulopathy and venous thromboembolic complications associated with COVID-19. 11 studies evaluating the frequency of registration of venous thromboembolic complications and 11 clinical recommendations on correction of coagulopathy published before May 22, 2020 have been studied. The frequency of venous thromboembolic complications was unexpectedly high: 8-13% in the general ward and 9-18% in the intensive care unit against the background of preventive measures. Preventive doses of anticoagulants, low-molecular weight heparins or unfractionated heparin are indicated to all hospitalized patients. Prolonged prophylaxis after discharge from hospital can be recommended for those at high risk of venous thromboembolic complications and low risk of bleeding. An increase in D-dimer may be considered as an indication for instrumental detection of venous thromboembolic complications. If there is a suspicion of venous thromboembolic complications, anticoagulant therapy at therapeutic doses can be started before the diagnosis is confirmed: during inpatient treatment preference should be given to low-molecular heparin or unfractionated heparin, after discharge from hospital it is recommended to transfer to direct oral anticoagulants for a period of at least 3 months. Routine prevention of venous thromboembolic complications in ambulatory patients is not recommended.